Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SRPT
#1927
Sarepta Therapeutics, Inc. - Common Stock
22.4
0
USD
+0.11%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+10.95%
Monthly Change
+45.17%
6 month change
+38.19%
Year Change
+22.40%
Previous Close
21.5
9
Open
21.4
5
Low
21.4
5
High
22.4
4
Volume
1 013
Markets
US Stock Market
Healthcare
Biotechnology
SRPT
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
79.42 M
87.15 M
87.98 M
93.86 M
97.03 M
104.99 M
105.63 M
Valuation ratios
Enterprise value
13.03 B
6.83 B
11.56 B
9.84 B
11.83 B
2.29 B
2.56 B
Price to earnings ratio
-23.98
-17.47
-15.55
-16.59
51.96
-3.02
-7.44
Price to sales ratio
24.61
10.43
11.72
7.15
6.9
0.98
1.18
Price to cash flow ratio
123.67
-16.51
-33.6
-17.74
-63.74
-10.49
15.73
Price to book ratio
17.45
7.89
28.4
10.34
8.59
1.89
0.42
Enterprise value to EBITDA ratio
-24.25
-16.19
-23.39
-44.04
46.25
-3.49
-25.93
Profitability ratios
Return on assets %
-0.19
-0.13
-0.22
-0.16
0.06
-0.21
-0
Return on equity %
-0.73
-0.45
-1.83
-0.62
0.15
-0.63
-0
Return on invested capital %
-387.46
-261.46
-324.22
-124.88
50.55
-160.7
7.12
Gross margin %
100
100
100
100
100
98.84
97.11
Operating margin %
-104.46
-65.5
-57.47
-21.54
11.47
-31.83
3.31
EBITDA margin %
-99.47
-60.08
-52.98
-17.97
13.45
-29.81
5.91
Net margin %
-102.6
-59.66
-75.4
-43.11
12.37
-32.45
-1.22
Liquidity ratios
Quick ratio
5.42
5.34
3.8
3.45
3.18
1.48
2.62
Current ratio
5.97
5.75
4.13
3.95
4.2
2.32
4.42
Inventory turnover
—
—
—
—
—
0.18
0.01
Asset turnover
0.22
0.23
0.3
0.39
0.53
0.66
0.13
Solvency ratios
Debt to assets ratio
0.33
0.35
0.49
0.38
0.29
0.25
0.27
Debt to equity ratio
1.3
1.18
4.01
1.44
0.74
0.73
0.55
Long term debt to total assets ratio
0.38
0.36
0.49
0.38
0.29
0.25
0.27
Long term debt to total equity ratio
1.47
1.21
4.01
1.44
0.74
0.73
0.55
Per share metrics
Operating cash flow per share
1.38
-5.45
-3.72
-5.42
-1.91
-2.05
1.37
EBIT per share
-7.24
-5.66
-6.12
-2.9
2.02
-6.99
-2.08
EBITDA per share
-6.89
-5.19
-5.65
-2.42
2.37
-6.54
-1.65
Total debt per share
12.73
13.5
17.64
13.4
10.54
8.28
8.04
Cash per share
24.99
26.16
22.94
18.31
12.56
9.39
7.48
Net current asset value per share
31.88
32.05
29.21
27.92
28.49
25.35
21.09
Tangible book value per share
9.77
11.42
4.4
9.3
14.16
11.1
14.2
Working capital per share
26.54
26.47
22.14
20.84
21.71
14.41
16.32
Book value per share
9.77
11.42
4.4
9.3
14.16
11.39
14.49
News
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
SRPT or PRTA: Which Is the Better Value Stock Right Now?